Clinical-stage biotech, Inhibrx filed the paperwork for its IPO. The company will raise up to $74,750,000 and intends to trade on NASDAQ under the symbol, “INBX.” Inhibrx is based in La Jolla, CA and has built a pipeline focused on oncology, orphan diseases and infectious diseases.
Its most advanced development programs are in Ph I trials. These include:
- INHIBRX-109 - a multivalent agonist of death receptor 5 with potential against multiple tumor types,
- INHIBRX-105 - a PD-L1 and 4-BB inhibitor with potential against PD-L1 expressing tumors.
- INHIBRX-103 - an mAb that has been licensed to Celgene
The company announced on May 21, 2019 that it had raised $40 million from Viking Global Partners. Since its inception, Inhibrx has raised $205 million, including $135 million in investor equity and debt and $70 million in licensing and grant payments.